ArticleACS medicinal chemistry letters2021
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate.
Abstract read
In one paragraph
Article in ACS medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.Journal for immunotherapy of cancer · 2026Trial
- Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Review
- Tumor microenvironment as niche constructed by cancer stem cells: Breaking the ecosystem to combat cancer.Journal of advanced research · 2025Review
- Role of the AKT signaling pathway in regulating tumor-associated macrophage polarization and in the tumor microenvironment: A review.Medicine · 2025Review
- Progress in structure-based drug development targeting chemokine receptors.Frontiers in pharmacology · 2025Review
- Chemokines as therapeutic targets for multiple sclerosis: a spatial and chronological perspective.Frontiers in immunology · 2025Review
- Angiopoietin-Like Protein 2 Expression in Tumor Cells Supports Tumor-Associated Macrophage-Induced Tumor Progression in Esophageal Cancer.Annals of surgical oncology · 2024Article
- Consensus, debate, and prospective on pancreatic cancer treatments.Journal of hematology & oncology · 2024Review
- Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer.Pharmaceutics · 2024Review
- CC Chemokine Family Members' Modulation as a Novel Approach for Treating Central Nervous System and Peripheral Nervous System Injury-A Review of Clinical and Experimental Findings.International journal of molecular sciences · 2024Review
- Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5.bioRxiv : the preprint server for biology · 2024Article
- Research progress on the role of tumor‑associated macrophages in tumor development and their use as molecular targets (Review).International journal of oncology · 2024Review
- Integrative analysis reveals chemokines CCL2 and CXCL5 mediated shear stress-induced aortic dissection formation.Heliyon · 2024Article
- Harmonizing hope: navigating the osteoarthritis melody through the CCL2/CCR2 axis for innovative therapeutic avenues.Frontiers in immunology · 2024Review
- Therapeutic developments in pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2024Review
- SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1.Theranostics · 2024Article
- Role of chemokines in the crosstalk between tumor and tumor-associated macrophages.Clinical and experimental medicine · 2023Review
- Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Robert J CherneyBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.ORCID https://orcid.org/0000-0002-6642-2834
Prakash AnjanappaBiocon Bristol Myers Squibb Research and Development Center, Bangalore 560099, India.
Kumaravel SelvakumarBiocon Bristol Myers Squibb Research and Development Center, Bangalore 560099, India.
Douglas G BattBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Gregory D BrownBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Anne V RoseBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Ragini VuppugallaBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Jing ChenBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Jian PangBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Songmei XuBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Melissa YardeBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Andrew J TebbenBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Venkatram Reddy PaidiBiocon Bristol Myers Squibb Research and Development Center, Bangalore 560099, India.
Mary Ellen CvijicBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Arvind MathurBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Joel C BarrishBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Sandhya MandlekarBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Qihong ZhaoBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.
Percy H CarterBristol Myers Squibb Company, Research and Early Development, Princeton, New Jersey 08540-4000, United States.ORCID https://orcid.org/0000-0002-5880-1164
Funding
No grant is acknowledged in the PubMed record.
Abstract
BMS-813160 (compound
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.